Early retinal volume changes after switching to brolucizumab in refractory neovascular age-related macular degeneration

1

This study evaluated early anatomical changes and intraocular inflammation following the switch to brolucizumab in nAMD patients refractory to other treatments.
2

Data from 23 patients showed significant decreases in central foveal retinal thickness and pigment epithelial detachment volume after switching to brolucizumab.
3

Intraocular inflammation was observed in three eyes, with varying degrees of anterior chamber inflammation and one case of vasculitis obliterans.
4

Despite a decrease in central foveal parameters, central retinal volume increased in eyes with intraocular inflammation, indicating a potential warning sign.
5

The study highlights the need for further prospective validation of the anatomical changes associated with brolucizumab therapy in nAMD patients.

1